- Home
- FUSE vs JSPR Comparison
FUSE vs JSPR Comparison
Compare FUSE & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUSE | JSPR |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 43.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FUSE | JSPR |
|---|---|---|
| Price | $1.30 | $1.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.13 |
| AVG Volume (30 Days) | ★ 939.4K | 406.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $1.11 |
| 52 Week High | $3.67 | $7.19 |
Technical Indicators
Market Signals| Indicator | FUSE | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 44.37 |
| Support Level | $1.23 | $1.11 |
| Resistance Level | $2.03 | $1.44 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 12.85 | 66.81 |
Price Performance
Historical ComparisonAbout FUSE Fusemachines Inc.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.